Opinion|Videos|December 21, 2023
Hepatotoxicity with KRASG12C Inhibitors in NSCLC
Author(s)Narjust Florez, MD
Dr Narjust Florez discusses the hepatoxicity associated with KRAS G12C inhibitors, noting both adagrasib and sotorasib pose liver damage risks, but real-world data suggests adagrasib may have a lower risk; she emphases the importance of considering other causes of hepatoxicity before attributing it solely to these therapies.
Advertisement
Episodes in this series
Advertisement
Related to this article
Xiuning Le, MD, PhD, explains how oncologists should approach HER2 biomarker testing following sevabertinib’s frontline approval in non–small cell lung cancer.
Subcutaneous amivantamab is safer and more convenient for patients compared with the intravenous formulation, according to Misako Nagasaka, MD, PhD.
Investigators are evaluating cesalatamig among patients with advanced cancer in the international phase 1/2 BiPAVE-001 trial.
The FDA granted fast track designation to the oral pan-KRAS inhibitor KST-6051 for patients with KRAS-mutant advanced or metastatic solid tumors.
Based on updated data from the TRUST-1 trial, a sNDA for taletrectinib has been approved by the FDA for patients with TKI-naive ROS1+ NSCLC.
Misako Nagasaka, MD, PhD, explains how subcutaneous amivantamab’s shorter administration time benefits patients and infusion centers.
Misako Nagasaka, MD, PhD, discusses PALOMA-2’s 70% 3-year survival rate compared with historical MARIPOSA data for intravenous amivantamab.
The OMNI-EGFR inhibitor BH-30643 produced a 45% objective response rate among patients with EGFR C797S–positive disease in the phase 1/2 SOLARA trial.
Advertisement
Advertisement
Trending on CancerNetwork
1
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
2
Neoantigen Vaccine Shows Encouraging Activity in Head and Neck Cancer
3
COA Warns That Price Negotiation for Medicare Part B Drugs Threatens Community Oncology
4
Using Intrathecal Dendritic Cells for Leptomeningeal Disease From Breast Cancer
5